Juliane Totzke

2015-2018 Pharmacology Duke University, Durham, NC 
"Juliane Totzke"
Mean distance: (not calculated yet)
BETA: Related publications


You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Scarneo S, Hughes P, Freeze R, et al. (2022) Development and Efficacy of an Orally Bioavailable Selective TAK1 Inhibitor for the Treatment of Inflammatory Arthritis. Acs Chemical Biology
Totzke J, Scarneo SA, Yang KW, et al. (2020) TAK1: a potent tumour necrosis factor inhibitor for the treatment of inflammatory diseases. Open Biology. 10: 200099
Scarneo SA, Eibschutz LS, Bendele PJ, et al. (2019) Pharmacological inhibition of TAK1, with the selective inhibitor takinib, alleviates clinical manifestation of arthritis in CIA mice. Arthritis Research & Therapy. 21: 292
Scarneo SA, Mansourati A, Eibschutz LS, et al. (2018) Genetic and pharmacological validation of TAK1 inhibition in macrophages as a therapeutic strategy to effectively inhibit TNF secretion. Scientific Reports. 8: 17058
Totzke J, Gurbani D, Raphemot R, et al. (2017) Takinib, a Selective TAK1 Inhibitor, Broadens the Therapeutic Efficacy of TNF-α Inhibition for Cancer and Autoimmune Disease. Cell Chemical Biology. 24: 1029-1039.e7
Crowe LB, Hughes PF, Alcorta DA, et al. (2017) A fluorescent Hsp90 probe demonstrates the unique association between extracellular Hsp90 and malignancy in vivo. Acs Chemical Biology
See more...